Optimizing quality of life for prostate cancer patients: a comprehensive approach
DOI:
https://doi.org/10.59188/eduvest.v5i2.33281Keywords:
lifestyle, prostate cancer, quality of life, survivorshipAbstract
This comprehensive review examines evidence-based interventions for optimizing quality of life in prostate cancer patients. Synthesizing a multifaceted approach, the review encompasses lifestyle modifications, educational support, cognitive-behavioural therapies, and survivorship care coordination. Robust evidence underscores the efficacy of integrating tailored exercise regimens, dietary modifications, and multidisciplinary care teams to address the multifaceted physical and psychological impacts of prostate cancer. Cognitive-behavioural approaches demonstrate significant value in mitigating emotional distress, while survivorship care coordination, interfacing with primary care, emerges as crucial for ensuring seamless transitions and long-term health optimization. Acknowledging inherent limitations, the review delineates key research recommendations to inform future investigations, emphasizing the dynamic nature of healthcare advancements in the ongoing pursuit of superior patient outcomes.
References
Bourke, L., Boorjian, S. A., Briganti, A., Klotz, L., Mucci, L., Resnick, M. J., Rosario, D. J., Skolarus, T. A., & Penson, D. F. (2015). Survivorship and improving quality of life in men with prostate cancer. European Urology, 68(3), 374–383.
Bourke, L., Gilbert, S., Hooper, R., Steed, L. A., Joshi, M., Catto, J. W. F., Saxton, J. M., & Rosario, D. J. (2014). Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. European Urology, 65(5), 865–872.
Habl, G., Uhl, M., Katayama, S., Kessel, K. A., Hatiboglu, G., Hadaschik, B., Edler, L., Tichy, D., Ellerbrock, M., & Haberer, T. (2016). Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized phase II study—the IPI trial. International Journal of Radiation Oncology* Biology* Physics, 95(1), 435–443.
Hamilton, R. J., Ding, K., Crook, J. M., O’Callaghan, C. J., Higano, C. S., Dearnaley, D. P., Horwitz, E. M., Goldenberg, S. L., Gospodarowicz, M. K., & Klotz, L. (2021). The association between statin use and outcomes in patients initiating androgen deprivation therapy. European Urology, 79(4), 446–452.
Huri, M., Huri, E., Kayihan, H., & Altuntas, O. (2015). Effects of occupational therapy on quality of life of patients with metastatic prostate cancer: a randomized controlled study. Saudi Medical Journal, 36(8), 954.
Kaushik, D., Shah, P. K., Mukherjee, N., Ji, N., Dursun, F., Kumar, A. P., Thompson Jr, I. M., Mansour, A. M., Jha, R., & Yang, X. (2022). Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. Prostate Cancer and Prostatic Diseases, 25(3), 531–538.
Klaff, R., Berglund, A., Varenhorst, E., Hedlund, P. O., Jǿnler, M., Sandblom, G., & 5, S. P. C. G. (SPCG) S. N. (2016). Clinical characteristics and quality‐of‐life in patients surviving a decade of prostate cancer with bone metastases. BJU International, 117(6), 904–913.
Lane, J. A., Donovan, J. L., Young, G. J., Davis, M., Walsh, E. I., Avery, K. N. L., Blazeby, J. M., Mason, M. D., Martin, R. M., & Peters, T. J. (2022). Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study). BJU International, 130(3), 370–380.
Langlais, C. S., Chen, Y.-H., Van Blarigan, E. L., Kenfield, S. A., Kessler, E. R., Daniel, K., Ramsdill, J. W., Beer, T. M., Graff, R. E., & Paich, K. (2022). Quality of life of prostate Cancer survivors participating in a remotely delivered web-based behavioral intervention pilot randomized Trial. Integrative Cancer Therapies, 21, 15347354211063500.
Mardani, A., Pedram Razi, S., Mazaheri, R., Haghani, S., & Vaismoradi, M. (2021). Effect of the exercise programme on the quality of life of prostate cancer survivors: A randomized controlled trial. International Journal of Nursing Practice, 27(2), e12883.
Morgans, A. K., Chen, Y.-H., Sweeney, C. J., Jarrard, D. F., Plimack, E. R., Gartrell, B. A., Carducci, M. A., Hussain, M., Garcia, J. A., & Cella, D. (2018). Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. Journal of Clinical Oncology, 36(11), 1088–1095.
Murthy, V., Maitre, P., Bhatia, J., Kannan, S., Krishnatry, R., Prakash, G., Bakshi, G., Pal, M., Menon, S., & Mahantshetty, U. (2020). Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiotherapy and Oncology, 145, 71–80.
Nabid, A., Carrier, N., Martin, A.-G., Bahary, J.-P., Lemaire, C., Vass, S., Bahoric, B., Archambault, R., Vincent, F., & Bettahar, R. (2018). Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. European Urology, 74(4), 432–441.
Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Ali, A., Amos, C. L., Attard, G., Chowdhury, S., Cook, A., & Cross, W. (2022). Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine, 19(6), e1003998.
Smith, M. R., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., & Kuss, I. (2021). Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. European Journal of Cancer, 154, 138–146.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rangga Juliar Adista, Jufriady Ismy
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
